Bangladesh vs Switzerland: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bangladesh
- Switzerland
How they compare
Bangladesh currently reports 479.38 deaths against 398.9 deaths in Switzerland, a difference of 80.48 deaths.
That makes Bangladesh's figure about 1.2 times Switzerland's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Switzerland ahead.
Bangladesh ranks 94th and Switzerland ranks 96th of 157 countries.
Switzerland has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bangladesh | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 136.75 deaths | 136.75 deaths | Switzerland |
| 2000s | 13.01 deaths | 599.76 deaths | 586.75 deaths | Switzerland |
| 2010s | 178.72 deaths | 490.23 deaths | 311.51 deaths | Switzerland |
| 2020s | 388.8 deaths | 411.15 deaths | 22.35 deaths | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bangladesh or Switzerland?
- Bangladesh, at 479.38 deaths against 398.9 deaths in Switzerland as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bangladesh and Switzerland?
- 80.48 deaths, with Bangladesh ahead.
- How many years of comparable data are there for Bangladesh and Switzerland?
- 35 years are reported by both, from 1990 to 2024.
- How do Bangladesh and Switzerland rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bangladesh ranks 94th and Switzerland ranks 96th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.